Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ironwood and AstraZeneca Begin Phase III China Trial for Linaclotide

publication date: Sep 13, 2013
Ironwood Pharma and AstraZeneca began their China Phase III clinical trial of linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C). Last year, the two companies announced a $150 million pact ($25 million upfront; the remainder in sales milestones) to develop the product in China. Although the relationship was described as a joint relationship, AstraZeneca has primary administrative responsibility for China operations. More details....

Stock Symbols: (NSDQ: IRWD) (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital